ENTITY

Hutchmed China Ltd (13 HK)

188

Analysis

Industrials • Hong Kong

HUTCHMED (China) Limited develops, manufactures, and sells pharmaceutical products. The Company offers drugs for oncology and autoimmune diseases treatment. HUTCHMED (China) markets its products worldwide.

more

Refresh

Exchange Announcement • 13 Dec 2024 08:00

Voluntary Announcement - Hutchmed To Receive Milestone Payment From Takeda Following First European Reimbursement For Fruzaqla (Fruquintinib)

Exchange Announcement • 12 Dec 2024 12:09

Voluntary Announcement - Hutchmed Announces Breakthrough Therapy Designation In China For Orpathys And Tagrisso Combination In Certain Lung Cancer Patients After Disease Progression On Egfr Inhibitor Therapy

Exchange Announcement • 03 Dec 2024 18:04

Voluntary Announcement - Hutchmed And Innovent Jointly Announce Nmpa Conditional Approval For Elunate (Fruquintinib) In Combination With Tyvyt (Sintilimab Injection) For The Treatment Of Advanced Endometrial Cancer

Exchange Announcement • 29 Nov 2024 16:37

Total Voting Rights

Exchange Announcement • 28 Nov 2024 18:05

Voluntary Announcement - Hutchmed Announces Continued Inclusion Of Orpathys (Savolitinib) In The National Reimbursement Drug List In China At Current Terms

Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.44.3

x